Williams Jones & Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Williams Jones & Associates’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-12,020	Closed	-$488K	–	397
2016 Q1	$488K	Sell	12,020 -8,907	-43%	-$381K	0.02%	208
2015 Q4	$1.36M	Sell	20,927 -6,933	-25%	-$455K	0.06%	148
2015 Q3	$1.97M	Sell	27,860 -4,065	-13%	-$397K	0.09%	142
2015 Q2	$3.55M	Sell	31,925 -3,485	-10%	-$375K	0.14%	127
2015 Q1	$3.34M	Sell	35,410 -2,275	-6%	-$255K	0.13%	130
2014 Q4	$4.22M	Buy	37,685 +10	+0%	+$893	0.17%	115
2014 Q3	$2.31M	Buy	37,675 +20,375	+118%	+$878K	0.11%	120
2014 Q2	$793K	Sell	17,300 -8,420	-33%	-$343K	0.04%	187
2014 Q1	$1.01M	Buy	25,720 +15,470	+151%	+$518K	0.02%	241
2013 Q4	$245K	Buy	+10,250	New	+$234K	0.01%	262

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Williams Jones & Associates's AGIO Position: Q2 2016 in Review

Williams Jones & Associates sold out of Agios Pharmaceuticals (AGIO) in Q2 2016, closing a stake of 12,020 shares — an estimated $488K sold.

Williams Jones & Associates first reported a position in AGIO in Q4 2013 and held it in 10 quarters. The position peaked at $4.22M in Q4 2014. 156 funds tracked by Wall St. Rank hold AGIO as of Q2 2016.

Williams Jones & Associates reported no remaining Agios Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Williams Jones & Associates sold 12,020 Agios Pharmaceuticals shares in Q2 2016, an estimated $488K.
Williams Jones & Associates first reported a position in Agios Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Williams Jones & Associates's Agios Pharmaceuticals position peaked at $4.22M in Q4 2014.
156 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2016.

Based on Williams Jones & Associates's 13F filing for Q2 2016, filed 15 Aug 2016.